- Home
- PZZA vs ETNB Comparison
PZZA vs ETNB Comparison
Compare PZZA & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZZA
- ETNB
- Stock Information
- Founded
- PZZA 1984
- ETNB 2018
- Country
- PZZA United States
- ETNB United States
- Employees
- PZZA N/A
- ETNB N/A
- Industry
- PZZA Restaurants
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- PZZA Consumer Discretionary
- ETNB Health Care
- Exchange
- PZZA Nasdaq
- ETNB Nasdaq
- Market Cap
- PZZA 1.4B
- ETNB 1.5B
- IPO Year
- PZZA 1993
- ETNB 2019
- Fundamental
- Price
- PZZA $48.64
- ETNB $9.03
- Analyst Decision
- PZZA Buy
- ETNB Strong Buy
- Analyst Count
- PZZA 10
- ETNB 9
- Target Price
- PZZA $52.33
- ETNB $26.63
- AVG Volume (30 Days)
- PZZA 1.2M
- ETNB 1.6M
- Earning Date
- PZZA 08-07-2025
- ETNB 08-07-2025
- Dividend Yield
- PZZA 3.78%
- ETNB N/A
- EPS Growth
- PZZA 8.47
- ETNB N/A
- EPS
- PZZA 2.28
- ETNB N/A
- Revenue
- PZZA $2,085,052,000.00
- ETNB N/A
- Revenue This Year
- PZZA $4.40
- ETNB N/A
- Revenue Next Year
- PZZA $0.98
- ETNB N/A
- P/E Ratio
- PZZA $21.38
- ETNB N/A
- Revenue Growth
- PZZA N/A
- ETNB N/A
- 52 Week Low
- PZZA $30.16
- ETNB $4.16
- 52 Week High
- PZZA $60.75
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- PZZA 62.29
- ETNB 50.63
- Support Level
- PZZA $43.94
- ETNB $9.07
- Resistance Level
- PZZA $49.91
- ETNB $9.62
- Average True Range (ATR)
- PZZA 1.78
- ETNB 0.38
- MACD
- PZZA 0.48
- ETNB 0.06
- Stochastic Oscillator
- PZZA 84.05
- ETNB 72.45
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).